The New York Eye & Ear Infirmary
Quick facts
Phase 3 pipeline
- PRFM treatment · Ophthalmology / Regenerative Medicine
PRFM (platelet-rich fibrin matrix) treatment uses autologous platelet-derived growth factors and fibrin scaffolding to promote tissue regeneration and healing.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- The New York Eye & Ear Infirmary portfolio CI brief
- The New York Eye & Ear Infirmary pipeline updates RSS
Frequently asked questions about The New York Eye & Ear Infirmary
What is The New York Eye & Ear Infirmary's pipeline?
The New York Eye & Ear Infirmary has 1 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include PRFM treatment.
Related
- Sector hub: All tracked pharma companies